Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer

By afschroeder • June 25, 2025

LeVee A, Peluso E, Lechner MG, Ruel N, Mortimer J, Kang I, Tsai K. Efficacy and immune-related adverse events of pembrolizumab with bone-modifying agents in female patients with breast cancer. Oncologist. 2025 Jun 4;30(6):oyaf134. doi: 10.1093/oncolo/oyaf134. PMID: 40549044.

Tags: breast cancer, Denosumab, Endocrinology, immune-related adverse events, immunotherapy, pembrolizumab, Publications

Care Coordination for High-Need, High-Cost Commercially Insured Patients: A Randomized Clinical Trial

Duru OK, Harwood J, Moin T, Takada S, Tseng CH, Saju R, Lee E, Fatehpuria A, Mangione CM. Care Coordination for High-Need, High-Cost Commercially Insured[...]

Genetic profiling of synchronous pituitary corticotroph adenomas

Zhang D, Tsai K, Santana C, Javaherian K, Lee M, Bergsneider M, Kim W, Wang MB, Vinters HV, Yan W, Heaney AP. Genetic profiling of[...]

A Veteran Presenting With Symptomatic Postprandial Episodes

Isaacs D, Kashefi M, Downs I, Weinreb J. A Veteran Presenting With Symptomatic Postprandial Episodes. Fed Pract. 2025 Feb;42(2):1-6. doi: 10.12788/fp.0541. Epub 2025 Feb 18.[...]